Annual Meeting Achived Material
23rd Annual PPAG Meeting Agenda and Learning Objectives
2014 Speaker Presentation With Objectives and Schedule
Wednesday, April 30, 2014
Iron Chelators
0180-0000-14-300-L01-P
Program Type: Knowledge-based
Clinical
Wednesday, April 30, 2014
10:00-10:20 am
Session Handout: www.ppag.org/23AM/mahto.pdf
Jaimi Mahto, PharmD
Clinical Pharmacist
University Of
At the end of this session, participants will be able to:
1. Role of Iron in our body.
2. Treatment of Iron overload, Role of Iron chelators.
3. Recent developments in Iron Chelation therapy.
The Facts of Factor VIII
0180-0000-14-301-L01-P
Program Type: Knowledge-based
Clinical
Wednesday, April 30, 2014
10:20-10:40 am
Session Handout: www.ppag.org/23AM/troutman.pdf
Kailey Troutman, PharmD
PGY1
At the end of this session, participants will be able to:
1. Review the pathophysiology of Hemophilia A
2. Discuss the current recommendations for management of hemophilia bleeding episodes
3. Identify the development of Factor VIII products used in hemophilia A
4. Recognize appropriate dosing and administration of Factor VIII
Update on MABs and NIBs
0180-0000-14-302-L01-P
Program Type: Knowledge-based
Clinical
Wednesday, April 30, 2014
10:40-11:00 am
Session Handout: www.ppag.org/23AM/parsons_pearl.pdf
Kerry Parsons, PharmD, BCOP
Clinical Pharmacist, Oncology
Children's of
At the end of this session, participants will be able to:
1. Describe pharmacology principles of monoclonal antibodies (MABs) relevant to pediatric cancer.
2. Describe pharmacology principles of tyrosine kinase inhibitors (NIBs) relevant to pediatric cancer.
3. Discuss major toxicities of MABs and NIBs relevant to developing a monitoring and supportive care regimen.
Pediatric Oncology: An Introduction to the Fundamental Building Blocks
0180-0000-14-303-L01-P
Program Type: Knowledge-based
General Session
Wednesday, April 30, 2014
11:00-11:30 am
Session Handout: www.ppag.org/23AM/koontz.pdf
Susannah Koontz, PharmD, BCOP
Oncology Consultant Pharmacist
Koontz Oncology Consulting LLC,
At the end of this session, participants will be able to:
1. Identify the most common cancers that occur in children
2. Describe the epidemiology and biology of commonly occurring cancers in children
3. List treatment modalities used in the management of pediatric malignancies
Tumor Lysis Syndrome
0180-0000-14-304-L01-P
Program Type: Knowledge-based
General Session
Wednesday, April 30, 2014
11:30-12:00 pm
Session Handout: www.ppag.org/23AM/dabb.pdf
Alix Dabb, PharmD
Clinical Pharmacy Specialist, Oncology
The
At the end of this session, participants will be able to:
1. Describe the pathophysiology of tumor lysis syndrome
2. Identify risk factors for developing tumor lysis syndrome
3. List the pharmacologic agents that may be utilized for prophylaxis and treatment of tumor lysis syndrome
Antiviral Prophylaxis: How NOT to Go Viral
0180-0000-14-305-L01-P
Program Type: Knowledge-based
Acute Care Track
Wednesday, April 30, 2014
1:30-2:00 pm
Session Handout: www.ppag.org/23AM/bernhardt.pdf
M. Brooke Bernhardt,
Clinical Pharmacy Specialist, Hematology and Oncology
At the end of this session, participants will be able to:
1. Recognize risk factors for viral infections in children with cancer
2. Examine the data on antiviral prophylaxis in children with cancer
3. Recommend potential guidelines for the use of antiviral prophylaxis in children wtih cancer
Combination Anti-fungal Therapy
0180-0000-14-306-L01-P
Program Type: Knowledge-based
Acute Care Track
Wednesday, April 30, 2014
2:00-2:30 pm
Session Handout: www.ppag.org/23AM/thackray.pdf
Jennifer Thackray, PharmD, BCPS
Clinical Pharmacy Specialist, Oncology
At the end of this session, participants will be able to:
1. Describe risk factors and common organisms responsible for invasive fungal infections (IFIs) in the immunocompromised patient
2. Identify clinical signs, symptoms and laboratory abnormalities suggestive of an IFI
3. Summarize current treatment recommendations for the management of IFIs
4. Evaluate novel treatment strategies for IFI (i.e. combination anti-fungal therapy)
Immunization Update for Immunosuppressed Patients
0180-0000-14-307-L01-P
Program Type: Knowledge-based
Acute Care Track
Wednesday, April 30, 2014
2:30-3:00 pm
Session Handout: www.ppag.org/23AM/eiland.pdf
Lea Eiland, PharmD., BCPS, FASHP
Clinical Professor and Associate Department Head of Pharmacy Practice
At the end of this session, participants will be able to:
1. List example diseases and medications that cause immunosuppression
2. Identify vaccines that are needed for hematopoietic stem cell transplant recipients
3. Describe risks of administering vaccines to patients with immunosuppressed household contacts
Oncologic Emergencies
0180-0000-14-308-L01-P
Program Type: Knowledge-based
Critical Care Track
Wednesday, April 30, 2014
1:30-2:00 pm
Session Handout: www.ppag.org/23AM/steinwedel.pdf
Erin Steinwedel, PharmD
Clinical specialist, Oncology
At the end of this session, participants will be able to:
1. Identify risk factors and complications of hyperleukocytosis and tumor lysis syndrome.
2. Formulate an appropriate laboratory monitoring plan for patients with tumor lysis syndrome.
3. Recommend a treatment plan for a patient with tumor lysis syndrome.
Novel Treatment Options for Chronic Graft-Versus-Host Disease in the Critical Care Setting
0180-0000-14-309-L01-P
Program Type: Knowledge-based
Critical Care Track
Wednesday, April 30, 2014
2:00-2:30 pm
Session Handout: www.ppag.org/23AM/barnett.pdf
Alina Barnett, PharmD, BCPS
Clinical Pharmacist
UCSF Benioff Children's Hospital,
At the end of this session, participants will be able to:
1. Review immunology, pathology and clinical manifestations of chronic graft-versus-host disease.
2. Compare novel treatment options for chronic graft-versus-host disease.
3. Discuss potential medication related infectious complications.
Hemophagocytic Lymphohistiocytosis
0180-0000-14-310-L01-P
Program Type: Knowledge-based
Critical Care Track
Wednesday, April 30, 2014
2:30-3:00 pm
Session Handout: www.ppag.org/23AM/price.pdf
Jessica Price, PharmD
Clinical Specialist, Hematology/Oncology
Children's Hospital of The King's Daughters (CHKD),
At the end of this session, participants will be able to:
1. Understand the pathophysiology of HLH.
2. List the diagnostic guidelines for HLH.
3. Understand how to treat a patient with HLH using current therapeutic guidelines.
Chemotherapy within an Electronic Health Record - Safety First
0180-0000-14-311-L04-P
Program Type: Knowledge-based
Acute Care Track
Wednesday, April 30, 2014
3:05-4:35 pm
Session Handout: www.ppag.org/23AM/baker-mcdaniel.pdf
Don Baker, PharmD, MBA
Clinical Decision Support Officer
St. Jude Children's
Ben McDaniel, PharmD
Medication Safety PGY2 Resident
St. Jude Children's
Richard Clark, PharmD
St. Jude Children’s Research Hospital, Memphis, Tennessee
At the end of this session, participants will be able to:
1. Be able to name 2 different types of clinical decision support mechanisms
2. Understand how both active and passive decision support play a role in enhancing medication safety within an electronic medical record system
3. Describe how complex chemotherapy regimens can be safely ordered, dispensed, and administered using an electronic medical record system.
Veno-occlusive Disease
0180-0000-14-312-L01-P
Program Type: Knowledge-based
Critical Care Track
Wednesday, April 30, 2014
3:05-3:35 pm
Session Handout: www.ppag.org/23AM/held.pdf
Kristin Held, PharmD, BCOP
Clinical Specialist
At the end of this session, participants will be able to:
1. Define veno-occlusive disease (VOD)
2. Identify the risk factors associated with VOD
3. Describe the clinical presentation of VOD
4. Recommend appropriate prophylactic therapies for VOD
5. Discuss management strategies available for and outcomes in managing VOD
Anthracycline-Induced Heart Disease
0180-0000-14-313-L01-P
Program Type: Knowledge-based
Critical Care Track
Wednesday, April 30, 2014
3:35-4:05 pm
Session Handout: www.ppag.org/23AM/ward.pdf
Deborah Ward, PharmD, BCOP, BCPS
Clinical pharmacy specialist
St Jude Children's Research Hospital, Memphis, Tennessee
At the end of this session, participants will be able to:
1. Define the underlying pathophysiology of anthracyline-induced cardiac toxicity
2. Identify patient specific risk factors for both acute and delayed cardiac toxicity
3. Describe the management of acute anthracycline-induced cardiac toxicity
Superior Vena Cava (SVC) Syndrome: Understanding Causes, Symptoms, and Treatment
0180-0000-14-314-L01-P
Program Type: Knowledge-based
Critical Care Track
Wednesday, April 30, 2014
4:05-4:35 pm
Session Handout: www.ppag.org/23AM/saylor.pdf
Matthew Saylor, PharmD, BCOP
Clinical pharmacy specialist, hematology/oncology
Novant Health - Presbyterian Medical Center, Charlotte, North Carolina
At the end of this session, participants will be able to:
1. To demonstrate understanding of SVC syndrome.
2. To determine appropriate treatment for SVC syndrome.
3. To extrapolate guidelines to fit their respective patient population.
Critical Care for Children with Cancer: The St. Jude Experience
0180-0000-14-315-L04-P
Keynote Address
Wednesday, April 30, 2014
4:40-5:40 pm
Session Handout: www.ppag.org/23AM/morrison.pdf
R. Ray Morrison, M.D.
Critical Care Division Chief
St. Jude Children's Research Hospital, Memphis, Tennessee
At the end of this session, participants will be able to:
1. Recognize common causes of respiratory failure in children who have cancer or who have undergone hematopoietic stem cell transplantation.
2. Identify risks associated with other end-organ dysfunction in pediatric cancer patients who experience respiratory failure.
3. Appreciate the medical and pharmaceutical complexity inherent in caring for critically ill children with cancer.
Thursday, May 1, 2014
Defibrotide for the prevention of hepatic veno-occlusive disease
0180-0000-14-316-L01-P
Program Type: Knowledge-based
Clinical Pearl
Thursday, May 1, 2014
8:00-8:20 am
Session Handout: www.ppag.org/23AM/mccabe.pdf
Tara McCabe, PharmD
Clinical pharmacy specialist, Hematology/Oncology
UF Health Shands Children's Hospital, Gainesville, Florida
At the end of this session, participants will be able to:
1. Identify risk factors for pediatric hematopoietic stem cell transplant patients to develop hepatic veno-occlusive disease
2. Compare and contrast the options for preventing hepatic veno-occlusive disease
3. Analyze the literature regarding the use of defibrotide for prophylaxis of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant patients
Implementation of Vincristine Minibags in Pediatric Cancer Patients
0180-0000-14-317-L01-P
Program Type: Knowledge-based
Clinical Pearl
Thursday, May 1, 2014
8:20-8:40 am
Session Handout: www.ppag.org/23AM/robertson.pdf
Jennifer Robertson, PharmD, BCPS
Medication Use Policy Coordinator
St. Jude Children's Research Hospital, Memphis, Tennessee
At the end of this session, participants will be able to:
1. Describe the dangers of dispensing vinca alkaloids in a syringe.
2. Identify issues for consideration when implementing vinca alkaloid minibags in pediatric cancer patients.
3. Describe how vinca alkaloid minibags were implemented in one institution.
Safe Handling of Oral Chemotherapy
0180-0000-14-318-L01-P
Program Type: Knowledge-based
Clinical Pearl
Thursday, May 1, 2014
8:40-9:00 am
Session Handout: www.ppag.org/23AM/devine.pdf
Meghan Devine, PharmD
Clinical pharmacy specialist, hematology and oncology
Carolina's HealthCare System/ Levine Children's Hospital, Charlotte, North Carolina
At the end of this session, participants will be able to:
1. List current guidelines and policies for safe handling of oral chemotherapeutic agents
2. Describe the risks associated with chemotherapeutic exposure
3. Discuss safe handling practices for health care providers and patients/caregivers
Forecasting the Future: Novel Treatment Strategies in Sickle Cell Disease
0180-0000-14-319-L01-P
Program Type: Knowledge-based
Acute Care Track
Thursday, May 1, 2014
9:00-9:45 am
Session Handout: www.ppag.org/23AM/elder.pdf
Joshua Elder, PharmD, BCPS
Hematology/Oncology/Stem Cell Transplant Clinical Specialist
Kosair Children's Hospital, Louisville, Kentucky
At the end of this session, participants will be able to:
1. Identify novel therapeutic agents to treat sickle cell disease.
2. Describe pharmacogenomic implications in the management of sickle cell disease.
3. Discuss curative therapeutic modalities in sickle cell disease.
What's Happenin' in Hemophilia
0180-0000-14-320-L01-P
Program Type: Knowledge-based
Acute Care Track
Thursday, May 1, 2014
9:45-10:30 am
Session Handout: www.ppag.org/23AM/trinkman.pdf
Heidi Trinkman, PharmD
Clinical Specialist, Hematology/Oncology
Cook Children's Medical Center, Fort Worth, Texas
At the end of this session, participants will be able to:
1. Describe the differences in the factor products available for the treatment of acute bleeds in patients with hemophilia.
2. List different treatment approaches available for patients with inhibitors.
3. Explain the technological advances in the field of hemophilia treatment and how they are changing the future of therapy.
Chemotherapy-induced Fever and Neutropenia
0180-0000-14-321-L01-P
Program Type: Knowledge-based
Critical Care Track
Thursday, May 1, 2014
9:00-9:45 am
Session Handout: www.ppag.org/23AM/bruce.pdf
Katie Bruce, PharmD
Clinical Pharmacist, Stem Cell Transplant
Vanderbilt Children's, Nashville, Tennessee
At the end of this session, participants will be able to:
1. Review risk associated with chemotherapy induced neutropenia
2. Review colony-stimulating factors used to shorten neutropenic period.
3. Evaluate literature available for empiric treatment of fever in a neutropenic patient.
Typhlitis (neutropenic enterocolitis)
0180-0000-14-322-L01-P
Program Type: Knowledge-based
Critical Care Track
Thursday, May 1, 2014
9:45-10:30 am
Session Handout: www.ppag.org/23AM/rohatgi.pdf
Radha Rohatgi, PharmD, BCOP
Clinical specialist, Hematology
Children's National Health Systems, Washington, D.C.
At the end of this session, participants will be able to:
1. Assess risks for typhlitis in pediatric patients receiving chemotherapy
2. Describe the clinical manifestations and diagnosis of typhlitis
3. Outline a plan utilizing therapeutic strategies and pharmacologic agents for the treatment of typhlitis.
Palliative Care Workshop
0180-0000-14-323-L01-P
Program Type: Knowledge-based
Acute Care Track
Thursday, May 1, 2014
10:35-12:05 pm
Session Handout: www.ppag.org/23AM/hagemann.pdf
Tracy Hagemann, PharmD, FCCP, FPPAG
Professor of Pharmacy and Director of Clinical Affairs
University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma
At the end of this session, participants will be able to:
1. Define palliative care practices in pediatric oncology, including end of life care.
2. Identify categories of palliative care pharmacotherapy.
3. Identify methods to provide palliative care pharmacotherapy to pediatric hematology and oncology patients.
4. Describe the role of the pediatric pharmacist in palliative care activities.
Update on Chemotherapy Drug Shortages
0180-0000-14-324-L01-P
Program Type: Knowledge-based
Critical Care Track
Thursday, May 1, 2014
10:35-11:05 am
Session Handout: www.ppag.org/23AM/hall-snyder-kassa.pdf
Laura Hall, PharmD
Clinical pharmacist, Oncology
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
Brandy Snyder, PharmD, BCOP, CPP
Clinical Specialist, Hematology/Oncology
Wake Forest Baptist Health, Winston-Salem, North Carolina
Mekdese Kassa, PharmD, BCOP
Oncology Pharmacy Operations and Clinical Manager
Alvin & Lois Lapidus Cancer Institute and The Herman and Walter Samuelson Children’s Hospital
Life Bridge Health, Baltimore, Maryland
At the end of this session, participants will be able to:
1. Define causes of drug shortages and chemotherapy drugs affected
2. Discuss impact of drug shortages on patient care
3. Identify policies to address chemotherapy drug shortages
4. Discuss Children’s Oncology Group’s (COG) recommendations for managing shortages
5. Describe strategies for prevention and management for drug shortages
6. Breakout session: Discuss chemotherapy drug shortages among participants and learn to apply COG recommendations and strategies
Navigating Asparaginase in Leukemia
0180-0000-14-325-L01-P
Program Type: Knowledge-based
Symposium
Thursday, May 1, 2014
12:05-1:30 pm
Session Handout: www.ppag.org/23AM/parsons_symposium.pdf
Kerry Parsons, PharmD, BCOP
Clinical Pharmacist, Oncology
Children's of Alabama, Birmingham, Alabama
At the end of this session, participants will be able to:
1. Discuss integration of asparaginase preparations in treatment of acute lymphoblastic leukemia.
2. Compare asparaginase products including pharmacology, dosing, administration, and toxicities.
3. Provide insights into prevention and management of asparaginase-related toxicities.
Voriconazole TDM review - challenging recommended dosing
0180-0000-14-326-L01-P
Program Type: Knowledge-based
General Session
Thursday, May 1, 2014
1:30-1:50 pm
Session Handout: www.ppag.org/23AM/stricherz.pdf
Melisa Stricherz, PharmD, BCOP
Clinical Pharmacist, BMT/Hematology/Oncology
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota
At the end of this session, participants will be able to:
1. Review Voriconazole PK
2. Discuss the differences between children and adults
3. Review Dosing and Therapeutic Drug Monitoring
4. Discuss how to choose a starting dose
5. Discuss when levels should be checked and understand the goals of therapy
6. Understand how to adjust levels to achieve goals.
Posaconazole pharmacokinetics and therapeutic drug monitoring
0180-0000-14-327-L01-P
Program Type: Knowledge-based
General Session
Thursday, May 1, 2014
1:50-2:10 pm
Session Handout: www.ppag.org/23AM/scott.pdf
Jeff Scott, PharmD, BCPS
Clinical Pharmacy Specialist
St. Jude Children's Research Hospital, Memphis, Tennessee
At the end of this session, participants will be able to:
1. Describe the pharmacokinetics of posaconazole
2. Assess barriers to absorption of posaconazole suspension
3. Summarize posaconazole therapeutic drug monitoring
Therapeutic Drug Monitoring-Beta-lactams
0180-0000-14-328-L01-P
Program Type: Knowledge-based
General Session
Thursday, May 1, 2014
2:10-2:30 pm
Session Handout: www.ppag.org/23AM/cies.pdf
Jeffrey Cies, PharmD, MPH, BCPS-AQ ID
Clinical Pharmacist, Critical Care and Infectious Diseases
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
At the end of this session, participants will be able to:
1. Provide brief overview/background of rationale behind therapeutic drug monitoring with beta-lactams
2. Discuss some recent evidence regarding therapeutic drug monitoring with beta-lactams
3. Provide an update regarding therapeutic drug monitoring with beta-lactams
Pediatric Resident Panel: Tips from Trainees: Getting and Rocking a Pediatric Residency
Student Session
Thursday, May 1, 2014
2:35-3:35 pm
Katie Andricopulos, PharmD
PGY2
University of Kentucky HealthCare, Lexington, Kentucky
Cady Ploessl, PharmD, BCPS
PGY2
Children's Hospital of Georgia, Augusta, Georgia
Josh Heffren, PharmD
PGY2
Children's Hospital Colorado, Aurora, Colorado
Mary Babico, PharmD
PGY2
University of Arizona Diamond Children's Center, Tuscon, Arizona
Andrea McMunn, PharmD
PGY2
The Johns Hopkins Hospital, Baltimore, Maryland
At the end of this session, participants will be able to:
1. Discuss reasons for choosing pediatric pharmacy as a specialty path
2. Provide insights on how students can prepare for residency
3. Discuss common mistakes that students and resident make
4. Provide advice for obtaining a residency position
Friday, May 2, 2014
The Paradigm Shift in Pediatric Drug Use: Therapeutic Orphans No More
0180-0000-14-329-L01-P
Program Type: Knowledge-based
The Yaffe Award Lecture: Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics
Friday, May 2, 2014
8:00-9:00 am
Session Handout: www.ppag.org/23AM/burckart.pdf
Gilbert Burckart, PharmD
Associate Director for Pediatrics
Office of Clinical Pharmacology
Office of Translational Sciences, CDER
U.S. Food and Drug Administration
At the end of this session, participants will be able to:
1. Discuss the present state of drug approvals for pediatric patients under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act
2. List the therapeutic areas in which the most failed pediatric trails have occurred, and the study design considerations for failed pediatric trials
3. Describe the steps that are necessary for a pediatric practitioner to become trained in pediatric drug research and join a national network of pediatric trials
Effect of a Pharmacist-Led Quality Improvement Initiative in a Pediatric Oncology Setting
0180-0000-14-330-L04-P
Program Type: Knowledge-based
Lexi-Comp Best Practice Award
Friday, May 2, 2014
9:05-9:15 am
Session Handout: www.ppag.org/23AM/elder_bestpractice.pdf
Joshua J. Elder, PharmD, BCPS
Clinical Specialist - Hematology/Oncology/Stem Cell Transplant
Kosair Children’s Hospital, Louisville, Kentucky
At the end of this session, participants will be able to:
1. Describe the initiation of two pharmacist-led committees as a quality improvement initiative in a pediatric oncology setting
2. Discuss the mission of the Chemotherapy Safety Committee and Children’s Oncology Group (COG) Committee
3. Review outcomes of Chemotherapy Safety Committee and COG Committee
Reduction of Broad-Spectrum Anti-microbial Use in a Tertiary Children’s Hospital after Anti-microbial Stewardship Program Guideline Implementation
0180-0000-14-331-L04-P
Lexi-Comp Best Practice Award
Friday, May 2, 2014
9:20-9:35 am
Session Handout: www.ppag.org/23AM/lee.pdf
Kelley Lee, PharmD, BCPS
Le Bonheur Children’s, Memphis, Tennessee
At the end of this session, participants will be able to:
1. Describe the two core strategies recommended for antimicrobial stewardship programs.
2. Understand how antibiotic guidelines can be implemented in a pediatric critical care unit.
3. Identify methods for decreasing broad-spectrum antibiotic use.
Medication Safety: Behaviors and Perceptions Among Parents and Guardians
0180-0000-14-332-L04-P
Program Type: Knowledge-based
Platform Presentation
Friday, May 2, 2014
9:35-9:45 am
Session Handout: www.ppag.org/23AM/matson.pdf
Kelly L. Matson, BSNutr, Pharm.D.
Associate Professor
University of Rhode Island, Kingston, Rhode Island
At the end of this session, participants will be able to:
1. Review current trends and statistics of non-medical use of prescription medications among adolescents
2. Summarize parents’ behaviors and perceptions of proper prescription medication use, storage and disposal
3. Discuss the pharmacist’s role in educating parents about proper medication use and dangers of misuse
Aminoglycoside pharmacokinetic parameter in infants with cystic fibrosis
0180-0000-14-333-L01-P
Platform Presentation
Friday, May 2, 2014
9:50-10:05 am
Session Handout: www.ppag.org/23AM/walleser_platform.pdf
Nathan Walleser, PharmD
Nationwide Children’s Hospital, Columbus, Ohio
At the end of this session, participants will be able to:
1. Identify known pharmacokinetic changes in patients with cystic fibrosis
2. Describe aminoglycoside pharmacokinetic parameters in infants with cystic fibrosis
3. Recommend an empiric aminoglycoside dose most likely to achieve goal pharmacokinetic parameters in infants with cystic fibrosis
Pediatric Pharmacy: Look to the Future
0180-0000-14-334-L04-P
The Helms Award Lecture: The Richard A. Helms Award of Excellence in Pediatric Pharmacy Practice
Friday, May 2, 2014
1:35-2:35 pm
Session Handout: www.ppag.org/23AM/luedtke.pdf
Sherry Luedtke, PharmD
Associate Professor, Pharmacy Practice
Texas Tech University School of Pharmacy, Amarillo, Texas
At the end of this session, participants will be able to:
1. Describe the changing face of pediatric pharmacy and its leadership.
2. Identify personal contributions which can impact the future of pediatric pharmacy.
3. Inspire future leaders of pediatric pharmacy.
Communicating with Pediatric Patients and Their Caregivers
0180-0000-14-335-L04-P
Program Type: Knowledge-based
Student Session
Friday, May 2, 2014
2:40-3:40 pm
Session Handout: www.ppag.org/23AM/schmidt.pdf
Deidra Schmidt, PharmD
Clinical pharmacist, Ambulatory Care
Children's of Alabama, Birmingham, Alabama
At the end of this session, participants will be able to:
1. Describe how communication strategies differ according to a child’s developmental stage/age
2. Identify four methods to improve communication with pediatric patients
3. Describe strategies for improving medication compliance in the pediatric patient population
Live at Monroe Carell Jr. Children’s Hospital at Vanderbilt
0180-0000-14-336-L04-P
Program Type: Knowledge-based
Hospital Tour
Friday, May 2, 2014
3:45-5:45 pm
At the end of this session, participants will be able to:
1. Explain the pharmacy practice model at MCJCHV
2. Describe clinical pharmacy services provided at MCJCHV
3. List technology utilized at MCJCHV through the medication use process
4. Describe implementation of innovative IV robotic technology systems for sterile product preparation
Saturday, May 3, 2014
Updates in Acute Otitis Media
0180-0000-14-337-L01-P
Program Type: Knowledge-based
Clinical Pearl
Saturday, May 3, 2014
8:00-8:20 am
Session Handout: www.ppag.org/23AM/lucas.pdf
Sarah Scarpace Lucas, PharmD, BCPS, FCSHP
Clinical Pharmacist
UCSF Benioff Children's Hospital, San Francisco, California
At the end of this session, participants will be able to:
1. Review pathophysiology, risk factors and diagnosis of Acute Otitis Media
2. Discuss the therapy management changes in the 2013 Acute Otitis Media Guidelines
3. Describe therapeutic treatment options for recurrent Otitis Media
4. Apply guidelines to therapy for selected patient cases
Paving the Way to Excellent Patient Care Through Change
0180-0000-14-338-L04-P
Program Type: Knowledge-based
Clinical Pearl
Saturday, May 3, 2014
8:20-8:40 am
Session Handout: www.ppag.org/23AM/cooper.pdf
Mary Temple-Cooper, MS, PharmD, BS, BCPS
Clinical Specialist
Hillcrest Hospital, Cleveland Clinic, Mayfield Heights, Ohio
At the end of this session, participants will be able to:
1. Discuss some of the changes at Hillcrest Hospital
2. Discuss some notable successes that came with change
3. Delineate key steps to facilitate change
4. Provide options to manage barriers and impacts of change on your staff
Diaper Dermatitis: A Most Irritating Issue
0180-0000-14-339-L01-P
Program Type: Knowledge-based
Clinical Pearl
Saturday, May 3, 2014
8:40-9:00 am
Session Handout: www.ppag.org/23AM/hoffmaster.pdf
Holly Hoffmaster, PharmD, BCPS
Clinical Pharmacist
Cleveland Clinic, Cleveland, Ohio
At the end of this session, participants will be able to:
1. Identify common types of diaper dermatitis
2. List risk factors that lead to diaper dermatitis
3. Describe methods of prevention and treatment of diaper dermatitis
4. Recognize when to consider escalating care
Updates in Cystic Fibrosis: A review of the literature and impact on care
0180-0000-14-340-L01-P
Program Type: Knowledge-based
General Session
Saturday, May 3, 2014
9:00-9:30 am
Session Handout: www.ppag.org/23AM/john.pdf
Bob John, PharmD, BCPS
Clinical Assistant Professor of Pediatric Pharmacotherapy
The University of Oklahoma College of Pharmacy-Tulsa, Tulsa, Oklahoma
At the end of this session, participants will be able to:
1. Evaluate literature published in the last year pertaining to the pharmacotherapy of cystic fibrosis
2. Describe the impact of recent data on the current care of patients with cystic fibrosis
Asthma Genotypes and Phenotypes and Endotypes, OH MY!
0180-0000-14-341-L01-P
Program Type: Knowledge-based
General Session
Saturday, May 3, 2014
9:30-10:00 am
Session Handout: www.ppag.org/23AM/lubsch.pdf
Lisa Lubsch, PharmD, AE-C
Clinical Associate Professor
Southern Illinois University-Edwardsville School of Pharmacy/Cardinal Glennon Children’s
Edwardsville, Illinois
At the end of this session, participants will be able to:
1. Define genotype, phenotype, and endotype and differentiate each in relation to asthma
2. Review current and theoretical classifications of asthma
3. Discuss how phenotype and endotype classifications may predict asthma treatment response
Nephrotic Syndrome - the Ins and Outs
0180-0000-14-342-L01-P
Program Type: Knowledge-based
Acute Care Track
Saturday, May 3, 2014
10:05-10:50 am
Session Handout: www.ppag.org/23AM/roehrs.pdf
Stacy Roehrs, B.S. Pharm, PharmD
Clinical Coordinator
Dayton Children's, Dayton, Ohio
At the end of this session, participants will be able to:
1. Describe the presenting symptoms of nephrotic syndrome.
2. List the usual treatments and management for nephrotic syndrome.
3. List the treatments for steroid resistant nephrotic syndrome.
Updates in Pediatric Chronic Renal Failure: What's New?
0180-0000-14-343-L01-P
Program Type: Knowledge-based
Acute Care Track
Saturday, May 3, 2014
10:50-11:35 pm
Session Handout: www.ppag.org/23AM/gill.pdf
Hardeep Gill, PharmD, BCPS
Clinical Pharmacist
UCSF Benioff Children's Hospital, San Francisco, California
At the end of this session, participants will be able to:
1. Evaluate the 2012-2013 KDIGO guidelines on children with CKD in regards to lipid management, BP control, and anemia & discuss the US KDOQI stance on these updates
2. Review the methods utilized in calculating eGFR in pediatrics with CKD. What is the role of newer eGFR formulas in pediatrics?
3. Compare and contrast the 2012 ISPD guidelines on treatment of peritonitis in PD & highlight the major differences from the 2000 guidelines.
IV Robotics
0180-0000-14-344-L04-P
Program Type: Knowledge-based
Professional Development
Saturday, May 3, 2014
10:05-11:35 am
Session Handout: www.ppag.org/23AM/carberry-humphreys.pdf
Beth Carberry, RPh, MBA, PLA
Director of Pharmacy
All Children's Hospital, St. Petersburg, Florida
Elizabeth Humphreys, PharmD
Director of Pharmacy
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
At the end of this session, participants will be able to:
1. Recognize the utility of IV robotics in a pediatric setting
2. Understand the decision process for selection of IV robots
3. Understand the implementation process for IV robotics
New Oral Anticoagulants for Venous Thromboembolism: The Search for the Ideal Anticoagulant for Pediatric Patients
0180-0000-14-345-L01-P
Program Type: Knowledge-based
Acute Care Track
Saturday, May 3, 2014
1:00-1:45 pm
Session Handout: www.ppag.org/23AM/hansen.pdf
Lizbeth Hansen, PharmD, BCPS
Clinical pharmacist
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota
At the end of this session, participants will be able to:
1. Understand the basics of developmental hemostasis and how they relate to existing options for pediatric anticoagulation
2. Compare theoretical benefits and risks of new oral anticoagulants (OAC) to current options for long term treatment and prophylaxis of venous thromboembolism
3. Discuss the clinical properties of each of the new OACs and the landmark adult trials that guide the use of them
4. Apply the concepts of developmental hemostasis to determine the potential role of new OACs in pediatric anticoagulation
Clonidine making a comeback
0180-0000-14-346-L01-P
Program Type: Knowledge-based
Acute Care Track
Saturday, May 3, 2014
1:45-2:30 pm
Session Handout: www.ppag.org/23AM/johnson.pdf
Pete Johnson, PharmD, BCPS
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma
At the end of this session, participants will be able to:
1. Describe the mechanism of action of alpha2 agonists in the management of pain.
2. Identify the role of clonidine for drug withdrawal, pain management, and opioid tolerance in children.
3. Provide recommendations for initial dosing and tapering of clonidine.
Non-Traditional PGY1 Residency Program
0180-0000-14-347-L04-P
Program Type: Knowledge-based
Professional Development
Saturday, May 3, 2014
1:00-2:30 pm
Session Handout: www.ppag.org/23AM/potts-grisso.pdf
Amy Potts, PharmD, BCPS
Assistant Director
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
Alison Grisso, PharmD
Clinical Pharmacist
Residency Program Director
Monroe Carell Jr, Children's Hospital at Vanderbilt, Nashville, Tennessee
At the end of this session, participants will be able to:
1. Recognize benefits and barriers to implementing a non-traditional residency
2. Develop strategies to achieve administrative and staff 'buy-in'
3. Understand the relevance of a non-traditional residency.
Drug Shortages-The Perverse Effects on Pediatric Patient Care
0180-0000-14-348-L04-P
Program Type: Knowledge-based
Keynote Address
Saturday, May 3, 2014
2:35-3:35 pm
Session Handout: www.ppag.org/23AM/vaneeckhout.pdf
John VanEeckhout, PharmD
Paventia Health
Former Vice President of Clinical Services for Children’s Hospital Association
At the end of this session, participants will be able to:
1. Discuss the recent trends of drug shortages.
2. Describe how drug shortages affect pediatric care provision, safety and treatment outcomes.
3. Discuss the impact of drug shortages on pediatrics hospitals procurement staffs and financial impact on the pharmacy drug costs.
4. Discuss current status of activities to reduce shortages
Sunday, May 4, 2014
Proton Pump Inhibitors in Infants
0180-0000-14-349-L01-P
Program Type: Knowledge-based
Clinical Pearl
Sunday, May 4, 2014
7:00-7:10 am
Session Handout: www.ppag.org/23AM/shelton.pdf
Chasity Shelton, PharmD, BCPS, BCNSP
Assistant Professor
The University of Tennessee Health Science Center, Memphis, Tennessee
At the end of this session, participants will be able to:
1. Identify the most commonly used proton pump inhibitors in the neonatal population.
2. List adverse effects associated with acid suppressive therapy in the neonatal intensive care unit population.
3. Recommend appropriate use of proton pump inhibitors in the neonatal population.
Subcutaneous IVIG
0180-0000-14-350-L01-P
Program Type: Knowledge-based
Clinical Pearl
Sunday, May 4, 2014
7:10-7:20 am
Session Handout: www.ppag.org/23AM/klein.pdf
www.ppag.org/23AM/klein_handout.pdf
Kristin Klein, PharmD, FPPAG
Clinical pharmacist specialist
University of Michigan, Ann Arbor, Michigan
At the end of this session, participants will be able to:
1. Compare and contrast the differences in dosing, interval, and infusion time of subcutaneous vs. intravenous immune globulin
2. List 3 advantages of subcutaneous administration of immune globulin when compared to intravenous administration of immune globulin
3. Compare and contrast the differences in associated costs between subcutaneous and intravenous immune globulin
Uses for the Sunlight Vitamin in Pediatrics
0180-0000-14-351-L01-P
Program Type: Knowledge-based
Clinical Pearl
Sunday, May 4, 2014
7:20-7:30 am
Session Handout: www.ppag.org/23AM/tobison.pdf
Jennifer Tobison, PharmD
Outpatient clinical specialist
Peyton Manning Children's Hospital at St. Vincent, Indianapolis, Indiana
At the end of this session, participants will be able to:
1. Recite recommended target levels for vitamin D
2. Identify patients at high risk for vitamin D insufficiency or deficiency
3. List current recommendations for vitamin D supplementation in the pediatric population
Inflammatory Bowel Disease
0180-0000-14-352-L01-P
Program Type: Knowledge-based
Acute Care Track
Sunday, May 4, 2014
7:30-8:15 am
Session Handout: www.ppag.org/23AM/gervase.pdf
Melissa Gervase, PharmD, AE-C
Clinical Pharmacist
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
At the end of this session, participants will be able to:
1. Understand the basic pathophysiology and clinical presentation of Inflammatory Bowel Disease (IBD), differentiating between Crohn’s and Ulcerative Colitis
2. Discuss treatment goals for the management of pediatric IBD
3. Understand how to select and appropriately monitor pharmacotherapy for a patient with IBD
Urea Cycle Disorders: The Role of the Pharmacist
0180-0000-14-353-L01-P
Program Type: Knowledge-based
Acute Care Track
Sunday, May 4, 2014
8:15-9:00 am
Session Handout: www.ppag.org/23AM/fuller.pdf
Paige Fuller, PharmD, BCPS
Clinical Pharmacy Specialist
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
At the end of this session, participants will be able to:
1. Explain the pathophysiology of Urea Cycle Disorders (UCDs).
2. Describe the acute initial medication management of UCDs.
3. Discuss the medications used in the chronic treatment of UCDs.
The Pharmacist's Role in Preparing Children for the Transition to Adult Care
0180-0000-14-354-L04-P
Program Type: Knowledge-based
Professional Development
Sunday, May 4, 2014
7:30-8:15 am
Session Handout: www.ppag.org/23AM/condren.pdf
Michelle Condren, PharmD, AE-C, CDE
Associate Professor and Department Chair of Pharmacy Practice
University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma
At the end of this session, participants will be able to:
1. Identify barriers to transitioning from adolescent to adult care that can impact health outcomes.
2. Discuss potential pharmacist interventions that promote readiness for transition to adult care.
3. Provide examples of pharmacist involvement that can facilitate transition to adult care within or outside the same institution.
Sharing Lessons Learned Through My Health Care Journey
0180-0000-14-355-L04-P
Program Type: Knowledge-based
Professional Development
Sunday, May 4, 2014
8:15-9:00 am
Session Handout: www.ppag.org/23AM/fiechtner.pdf
Helen Fiechtner, PharmD, FPPAG
Clinical Pharmacist
At the end of this session, participants will be able to:
1. Discuss how the signs and symptoms of evolving immune / auto-immune / inflammatory / anti-inflammatory disorders can change over time which can affect appropriate and timely diagnosis.
2. Discuss how immune / auto-immune / inflammatory / anti-inflammatory disorders can change the signs and symptoms of other diseases.
3. Discuss how evolving immune / auto-immune / inflammatory / anti-inflammatory disorders can change medication adverse reactions.
4. Explain the usefulness of a patient history and treatment information sheet for a medically complex patient.
Cerebral Palsy
0180-0000-14-356-L01-P
Program Type: Knowledge-based
Acute Care Track
Sunday, May 4, 2014
9:00-9:45 am
Session Handout: www.ppag.org/23AM/billings.pdf
Cassie Billings, B.S, PharmD
Clinical Pharmacy Specialist-Pediatrics
James and Connie Maynard Children's Hospital, Greenville, North Carolina
At the end of this session, participants will be able to:
1. Discuss the benefits and risks of different treatment modalities for spasticity.
2. Summarize options for the management of drooling in patients with cerebral palsy.
3. Recognize patients who are at risk for osteopenia and design a therapeutic strategy for prevention.
Psychoactive Medications in Breastfeeding
0180-0000-14-357-L01-P
Program Type: Knowledge-based
Acute Care Track
Sunday, May 4, 2014
9:45-10:30 am
Session Handout: www.ppag.org/23AM/burkey.pdf
Betsy Walters Burkey, PharmD, BCPS
Clinical specialist
Fairview Hospital / Cleveland Clinic Children's Hospital, Cleveland, Ohio
At the end of this session, participants will be able to:
1. Describe the new proposed FDA drug labeling changes for medications in regards to lactation
2. Recognize which infants are at the highest risk for adverse effects when potentially exposed to a medication through breast milk
3. Utilize LactMed to evaluate real-time available medication information when asked questions about a psychoactive medications in breast-feeding
Stepping out of practice into management
0180-0000-14-358-L04-P
Program Type: Knowledge-based
Professional Development
Sunday, May 4, 2014
9:00-10:30 am
Session Handout: www.ppag.org/23AM/denson-bobo-whitehill.pdf
Brenda Denson, PharmD
Investigational Studies Pharmacist
Childrens of Alabama, Birmingham, Alabama
Kelly Bobo, PharmD, BCPS
Clinical Manager
Le Bonheur Children's Hospital, Memphis, Tennessee
Jordan Whitehill,PharmD, BCPS
Clinical Manager
Children’s Medical Center Dallas, Dallas, Texas
At the end of this session, participants will be able to:
1. Describe the shortage of trained pharmacy leaders in hospital and other practice settings
2. Outline available training programs for pharmacy leadership development
3. Construct a decision tree for career path changes including pros, cons, challenges, and work-life balance
4. Review things you never thought you would need or want to know related to management
Ketogenic Diet Protocols and Resources
0180-0000-14-359-L01-P
Program Type: Knowledge-based
General Session
Sunday, May 4, 2014
10:45-11:05 am
Session Handout: www.ppag.org/23AM/bogenschutz.pdf
Monica Bogenschutz, PharmD, BCPS
Clinical pharmacist
American Family Children's Hospital/University of Wisconsin Hospital and Clinics, Madison, Wisconsin
At the end of this session, participants will be able to:
1. Briefly review Ketogenic Diet Therapy and rationale for use
2. Discuss stages of therapy initiation and pharmacist role
3. Identify medication related resources
Acetaminophen-The Changing Times
0180-0000-14-360-L01-P
Program Type: Knowledge-based
General Session
Sunday, May 4, 2014
11:05-11:25 am
Session Handout: www.ppag.org/23AM/benefield.pdf
Emily Benefield, PharmD, BCPS
Clinical pharmacist
Primary Children's Hospital, Salt Lake City, Utah
At the end of this session, participants will be able to:
1. Describe the FDA recommendations for the maximum daily acetaminophen dosage.
2. Identify an area for potential adverse events associated with acetaminophen containing products.
3. Develop a plan to minimize the risk for acetaminophen related adverse events for inpatient pharmacy services.
Propranolol for Infantile Hemangioma
0180-0000-14-361-L01-P
Program Type: Knowledge-based
General Session
Sunday, May 4, 2014
11:25-11:45 am
Session Handout: www.ppag.org/23AM/zuckerman.pdf
Andrea Zuckerman, PharmD
Clinical Pharmacist
Cleveland Clinic Children’s, Cleveland Ohio
At the end of this session, participants will be able to:
1. Describe clinical features and pathogenesis of infantile hemangioma (IH)
2. Identify characteristics of IH for which drug therapy may be indicated
3. Compare and contrast efficacy and adverse effects of standard therapy and propranolol for treatment of IH
4. Describe the available evidence for use of propranolol in IH and consensus statement recommendations.
Getting the Most Out of Your Day without Losing Your Mind
0180-0000-14-362-L04-P
Program Type: Knowledge-based
General Session
Sunday, May 4, 2014
11:45-12:45 am
Session Handout: www.ppag.org/23AM/moffett.pdf
Brady Moffett, PharmD, MPH
Clinical pharmacy specialist
Texas Children's Hospital, Houston, Texas
At the end of this session, participants will be able to:
1. Understand strategies for achieving and maintaining personal productivity
2. Identify strategies for completing large or complex projects
3. Understand the psychology behind procrastination
